← Back to Search

Motivational Interviewing for Substance Use Disorders

Led By Margo Hurlocker, PhD
Research Sponsored by University of New Mexico
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up baseline and 1 year
Awards & highlights


This trial will test whether using Motivational Interviewing at Intake (MII) with adults seeking outpatient addiction treatment leads to better engagement with treatment and understand why this is the case. Personnel feedback will be gathered on whether MII is feasible to implement into standard practice.

Who is the study for?
This trial is for English-speaking adults seeking outpatient treatment for alcohol or drug use, who are willing to follow study procedures and have given informed consent. It's also open to staff at the treatment programs. Participants must not be physically dependent on substances at the time of intake.Check my eligibility
What is being tested?
The study compares two approaches: usual intake procedures versus Motivational Interviewing at Intake (MII) to see which is more effective in engaging clients in addiction treatment. The trial will also assess how easy it is to integrate MII into regular practice.See study design
What are the potential side effects?
Since this trial involves counseling techniques rather than medication, traditional side effects are not expected. However, participants may experience emotional discomfort discussing their substance use during motivational interviewing sessions.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants who attended the first outpatient treatment program session based on electronic medical record review
Number of participants who completed the three-month outpatient treatment program based on electronic medical record review
Number of treatment sessions attended during the three-month outpatient treatment program based on electronic medical record review
Secondary outcome measures
Change from baseline in client readiness to enter treatment on the University of Rhode Island Change Assessment Scale (URICA) at 1 hour post-intake
Score on therapeutic alliance on the Working Alliance Inventory (WAI) at 1-hour post-intake
Other outcome measures
Change from baseline in organizational capability to change on the Change Process Capability Questionnaire (CPCQ) at Year 1
Change from baseline in organizational readiness to change on the Readiness for Organizational Change (ROC) at 1 year
Change from baseline in organizational readiness to change on the Texas Christian University-Organizational Readiness to Change (TCU-ORC) at 1 year

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Motivational Interviewing at Intake (MII)Experimental Treatment1 Intervention
Clients allocated to the MII condition will receive a 90-minute pure Motivational Interviewing (MI) session.
Group II: Intake as Usual (IAU)Active Control1 Intervention
Clients allocated to the IAU condition will receive the 90-minute standard assessment that is delivered to all clients entering intensive outpatient program (IOP)/outpatient program (OP).

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Substance Use Disorders (SUDs) include Cognitive Behavioral Therapy (CBT), Motivational Interviewing (MI), and Contingency Management (CM). CBT helps patients identify and modify distorted thinking patterns and behaviors that contribute to substance use, promoting healthier coping strategies. MI enhances client engagement by addressing ambivalence and fostering intrinsic motivation for change, making it particularly effective at the intake stage. CM uses positive reinforcement, such as vouchers or rewards, to encourage abstinence and adherence to treatment. These mechanisms are crucial as they address the psychological and behavioral aspects of addiction, improving treatment retention and outcomes for SUD patients.
Self-awareness deficits associated with lower treatment motivation in cocaine addiction.A review of psychosocial interventions for amphetamine use.

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,503 Previous Clinical Trials
2,625,433 Total Patients Enrolled
University of New MexicoLead Sponsor
376 Previous Clinical Trials
3,528,507 Total Patients Enrolled
Margo Hurlocker, PhDPrincipal InvestigatorUniversity of New Mexico

Media Library

Intake as Usual (IAU) Clinical Trial Eligibility Overview. Trial Name: NCT05489068 — N/A
Substance Use Disorders Research Study Groups: Intake as Usual (IAU), Motivational Interviewing at Intake (MII)
Substance Use Disorders Clinical Trial 2023: Intake as Usual (IAU) Highlights & Side Effects. Trial Name: NCT05489068 — N/A
Intake as Usual (IAU) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05489068 — N/A
~10 spots leftby Oct 2024